We believe cancer research and service improvement are integrally linked and should be driven by the needs and priorities of the community. Our mission is to build a culture of collaboration and innovation that transcends organisational boundaries and drives improved cancer outcomes. MPCCC priorities are to:

• Design and deliver a holistic and equitable cancer research and improvement agenda
• Build capacity for innovations in cancer treatments by linking discovery, pre-clinical and clinical research
• Drive improvements in cancer care through the strategic use of data to inform priorities and measure outcomes
• Establish and maintain strategic collaborations that align cancer research and improvement activities with health and research policy agenda
• Use appropriate governance and processes to lead and promote a world-class cancer research and improvement agenda.

You can find out more about Monash Partners Comprehensive Cancer Consortium work here or follow MPCCC on Twitter and LinkedIn .

The Theme is led by the Monash Partners Comprehensive Cancer Consortium Executive Members: Prof. Melissa Southey and Prof. Mark Shackleton.

The EMCR Co-Lead is Edmond Kwan, a clinician-scientist and medical oncologist at Eastern Health, leading translational research in cancer genomics and biomarkers.

Professor Melissa C. Southey OAM

Read More

Is the Co-Research Director of the Monash Partners Comprehensive Cancer Consortium. As a molecular geneticist (FHGSA) and a Founding Fellow of the Faculty of Science, Royal College of Pathologists of Australasia (FFSc, RCPA). She is Chair of Precision Medicine, School of Clinical Sciences at Monash Health, Director of Monash University’s new Biobanking Victoria initiative, based at the Monash Health Translation Precinct.

Professor Mark Shackleton MBBS PhD FRACP

Read More

Is Co-Research Director of the Monash Partners Comprehensive Cancer Consortium, the Director of Oncology at Alfred Health and Professor of Oncology in the Department of Medicine, Monash Univerisity. Most recently a Medical Oncologist and Head of the Cancer Development and Treatment Laboratory at the Peter MacCallum Cancer Centre .

You can find out more about Monash Partners Comprehensive Cancer Consortium team here or follow MPCCC on Twitter and LinkedIn

Monash Partners is proud to support the following projects within this Theme:

Using smart technology to more effectively and efficiently monitor the quality of cancer care
Professor John Zalcberg

Optimising lung cancer outcomes by using a clinical quality registry framed around value-based health care
Professor John Zalcberg

Innovative use of AI for antifungal stewardship in patients with blood cancer
Dr Michelle Ananda-Rajah

Real time surveillance of fungal infections to improve clinical care
Dr Michelle Ananda-Rajah

Improving access to new treatments for patients with Myeloma through a new clinical trials platform
Professor Andrew Spencer

Lung Cancer Clinical Quality Registry: a state-wide approach to monitoring and improving lung cancer care
Professor John Zalcberg

Establishing a Monash Partners national reference centre for molecular monitoring of residual disease in acute myeloid leukaemia
Associate Professor Andrew Wei

Exploratory analysis of circulating-free RNA as a non-invasive biomarker in multiple myeloma (MM) utilising the Myeloma and Related Diseases Registry (MRDR) and the Australasian Myeloma Research consortium (AMARC)
Professor Andrew Spencer

The PRECISE assay: Personalised medicine for cancer patients using next-generation sequencing
Dr Mark Waltham